CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 4, 2019--
Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company
focused on the development and commercialization of therapeutics for
patients with kidney disease, granted 11 newly-hired employees options
to purchase an aggregate of 41,900 shares of Akebia’s common stock on
January 31, 2019, as inducements material to each such employee’s
entering into employment with Akebia. The options were granted in
accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $5.51 per share, which is equal to
the closing price of Akebia’s common stock on the grant date. Each stock
option vests over four years, with 25% of the shares vesting on the
first anniversary of the grant date and the remaining 75% of shares
vesting quarterly thereafter, in each case, subject to the new
employee’s continued service with the company. Each stock option has a
10-year term and is subject to the terms and conditions of the company’s
Inducement Award Program and a stock option agreement covering the grant.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical
company focused on the development and commercialization of therapeutics
for patients with kidney disease. The company was founded in 2007 and is
headquartered in Cambridge, Massachusetts. For more information, please
visit our website at www.akebia.com
which does not form a part of this release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190204005728/en/
Source: Akebia Therapeutics, Inc.
Akebia Therapeutics Contact
Forst / Maghan Meyers